EGFR and pneumonia: It was considered that immunotherapy may be less effective for driver gene positive cancer and in elderly people; in addition, it has also been previously reported that there is a risk of increased drug‐induced pneumonia after immunotherapy there is a risk of drug‐induced pneumonia of EGFR‐TKI such as osimertinib.26